Skip to main content
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience 6/2009

01.09.2009 | Short Communication

Accelerated clinical decline in well-educated patients with frontotemporal lobar degenerations

verfasst von: Robert Perneczky, Corina Pohl, Susanne Bornschein, Hans Förstl, Alexander Kurz, Janine Diehl-Schmid

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Education seems to protect against symptoms of neurodegeneration, but highly educated individuals experience faster cognitive decline after the onset of dementia. No studies on the effects of education on the clinical course in frontotemporal lobar degenerations (FTLD) exist. The aim of the study was to explore the effect of education on the rate of clinical deterioration in patients with FTLD. Thirty-five patients with FTLD were recruited and followed up for 20 months in average. A correlation was calculated between years of education and monthly rate of change on the clinical dementia rating scale sum of the boxes (CDR-SOB). A linear regression analysis with the CDR-SOB monthly rate of change as dependent, and the educational years and other variables possibly associated with the rate of clinical decline as independent variables was performed. There was a significant positive association between education and CDR-SOB monthly rate of change, indicating a faster decline in the well-educated. Education was the only significant predictor of clinical deterioration.
Literatur
1.
Zurück zum Zitat Anneser JM, Jox RJ, Borasio GD (2007) Inappropriate sexual behaviour in a case of ALS and FTD: successful treatment with sertraline. Amyotroph Lateral Scler 8:189–190PubMedCrossRef Anneser JM, Jox RJ, Borasio GD (2007) Inappropriate sexual behaviour in a case of ALS and FTD: successful treatment with sertraline. Amyotroph Lateral Scler 8:189–190PubMedCrossRef
2.
Zurück zum Zitat Bennett DA, Wilson RS, Schneider JA, Evans DA, Mendes de Leon CF, Arnold SE, Barnes LL, Bienias JL (2003) Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology 60:1909–1915PubMed Bennett DA, Wilson RS, Schneider JA, Evans DA, Mendes de Leon CF, Arnold SE, Barnes LL, Bienias JL (2003) Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology 60:1909–1915PubMed
3.
Zurück zum Zitat Borroni B, Grassi M, Agosti C, Premi E, Archetti S, Alberici A, Bellelli G, Caimi L, Di Luca M, Padovani A (2008) Establishing short-term prognosis in frontotemporal lobar degeneration spectrum: role of genetic background and clinical phenotype. Neurobiol Aging Borroni B, Grassi M, Agosti C, Premi E, Archetti S, Alberici A, Bellelli G, Caimi L, Di Luca M, Padovani A (2008) Establishing short-term prognosis in frontotemporal lobar degeneration spectrum: role of genetic background and clinical phenotype. Neurobiol Aging
4.
Zurück zum Zitat Broe M, Hodges JR, Schofield E, Shepherd CE, Kril JJ, Halliday GM (2003) Staging disease severity in pathologically confirmed cases of frontotemporal dementia. Neurology 60:1005–1011PubMed Broe M, Hodges JR, Schofield E, Shepherd CE, Kril JJ, Halliday GM (2003) Staging disease severity in pathologically confirmed cases of frontotemporal dementia. Neurology 60:1005–1011PubMed
5.
Zurück zum Zitat Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308–2314PubMed Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308–2314PubMed
6.
Zurück zum Zitat Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ (2004) Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl) 172:400–408CrossRef Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ (2004) Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl) 172:400–408CrossRef
7.
Zurück zum Zitat Diehl-Schmid J, Forstl H, Perneczky R, Pohl C, Kurz A (2008) A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry 23:754–759PubMedCrossRef Diehl-Schmid J, Forstl H, Perneczky R, Pohl C, Kurz A (2008) A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry 23:754–759PubMedCrossRef
8.
Zurück zum Zitat Diehl-Schmid J, Pohl C, Perneczky R, Forstl H, Kurz A (2006) Behavioral disturbances in the course of frontotemporal dementia. Dement Geriatr Cogn Disord 22:352–357PubMedCrossRef Diehl-Schmid J, Pohl C, Perneczky R, Forstl H, Kurz A (2006) Behavioral disturbances in the course of frontotemporal dementia. Dement Geriatr Cogn Disord 22:352–357PubMedCrossRef
9.
Zurück zum Zitat Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: a frontal assessment battery at bedside. Neurology 55:1621–1626PubMed Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: a frontal assessment battery at bedside. Neurology 55:1621–1626PubMed
10.
Zurück zum Zitat Fellgiebel A, Muller MJ, Hiemke C, Bartenstein P, Schreckenberger M (2007) Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry 8:123–126PubMedCrossRef Fellgiebel A, Muller MJ, Hiemke C, Bartenstein P, Schreckenberger M (2007) Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry 8:123–126PubMedCrossRef
11.
Zurück zum Zitat Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRef Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRef
12.
Zurück zum Zitat Graff-Radford NR, Ferman TJ, Lucas JA, Johnson HK, Parfitt FC, Heckman MG, Todd M, Sadowsky C, Epstein DE, Crook JE (2006) A cost effective method of identifying and recruiting persons over 80 free of dementia or mild cognitive impairment. Alzheimer Dis Assoc Disord 20:101–104PubMedCrossRef Graff-Radford NR, Ferman TJ, Lucas JA, Johnson HK, Parfitt FC, Heckman MG, Todd M, Sadowsky C, Epstein DE, Crook JE (2006) A cost effective method of identifying and recruiting persons over 80 free of dementia or mild cognitive impairment. Alzheimer Dis Assoc Disord 20:101–104PubMedCrossRef
13.
Zurück zum Zitat Haroutunian V, Purohit DP, Perl DP, Marin D, Khan K, Lantz M, Davis KL, Mohs RC (1999) Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch Neurol 56:713–718PubMedCrossRef Haroutunian V, Purohit DP, Perl DP, Marin D, Khan K, Lantz M, Davis KL, Mohs RC (1999) Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch Neurol 56:713–718PubMedCrossRef
14.
Zurück zum Zitat Harvey RJ, Skelton-Robinson M, Rossor MN (2003) The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry 74:1206–1209PubMedCrossRef Harvey RJ, Skelton-Robinson M, Rossor MN (2003) The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry 74:1206–1209PubMedCrossRef
15.
Zurück zum Zitat Hindmarch I, Lehfeld H, de Jongh P, Erzigkeit H (1998) The Bayer activities of daily living scale. Dement Geriatr Cogn Disord 9:20–26PubMedCrossRef Hindmarch I, Lehfeld H, de Jongh P, Erzigkeit H (1998) The Bayer activities of daily living scale. Dement Geriatr Cogn Disord 9:20–26PubMedCrossRef
16.
Zurück zum Zitat Kertesz A, Davidson W, Fox H (1997) Frontal behavioral inventory: diagnostic criteria for frontal lobe dementia. Can J Neurol Sci 24:29–36PubMed Kertesz A, Davidson W, Fox H (1997) Frontal behavioral inventory: diagnostic criteria for frontal lobe dementia. Can J Neurol Sci 24:29–36PubMed
17.
Zurück zum Zitat Kertesz A, Morlog D, Light M, Blair M, Davidson W, Jesso S, Brashear R (2008) Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord 25:178–185PubMedCrossRef Kertesz A, Morlog D, Light M, Blair M, Davidson W, Jesso S, Brashear R (2008) Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord 25:178–185PubMedCrossRef
18.
Zurück zum Zitat Kipps CM, Nestor PJ, Dawson CE, Mitchell J, Hodges JR (2008) Measuring progression in frontotemporal dementia: implications for therapeutic interventions. Neurology 70:2046–2052PubMedCrossRef Kipps CM, Nestor PJ, Dawson CE, Mitchell J, Hodges JR (2008) Measuring progression in frontotemporal dementia: implications for therapeutic interventions. Neurology 70:2046–2052PubMedCrossRef
19.
Zurück zum Zitat Klempin F, Kempermann G (2007) Adult hippocampal neurogenesis and aging. Eur Arch Psychiatry Clin Neurosci 257:271–280PubMedCrossRef Klempin F, Kempermann G (2007) Adult hippocampal neurogenesis and aging. Eur Arch Psychiatry Clin Neurosci 257:271–280PubMedCrossRef
20.
Zurück zum Zitat Kuhn HG, Cooper-Kuhn CM, Boekhoorn K, Lucassen PJ (2007) Changes in neurogenesis in dementia and Alzheimer mouse models: are they functionally relevant? Eur Arch Psychiatry Clin Neurosci 257:281–289PubMedCrossRef Kuhn HG, Cooper-Kuhn CM, Boekhoorn K, Lucassen PJ (2007) Changes in neurogenesis in dementia and Alzheimer mouse models: are they functionally relevant? Eur Arch Psychiatry Clin Neurosci 257:281–289PubMedCrossRef
21.
Zurück zum Zitat Lebert F, Pasquier F (1999) Trazodone in the treatment of behaviour in frontotemporal dementia. Hum Psychopharmacol Clin Exp 14:279–281CrossRef Lebert F, Pasquier F (1999) Trazodone in the treatment of behaviour in frontotemporal dementia. Hum Psychopharmacol Clin Exp 14:279–281CrossRef
22.
Zurück zum Zitat Lebert F, Stekke W, Hasenbroekx C, Pasquier F (2004) Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord 17:355–359PubMedCrossRef Lebert F, Stekke W, Hasenbroekx C, Pasquier F (2004) Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord 17:355–359PubMedCrossRef
23.
Zurück zum Zitat Mendez MF, Shapira JS, McMurtray A, Licht E (2007) Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry 15:84–87PubMedCrossRef Mendez MF, Shapira JS, McMurtray A, Licht E (2007) Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry 15:84–87PubMedCrossRef
24.
Zurück zum Zitat Moretti R, Torre P, Antonello RM, Cazzato G, Bava A (2003) Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol 49:13–19PubMedCrossRef Moretti R, Torre P, Antonello RM, Cazzato G, Bava A (2003) Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol 49:13–19PubMedCrossRef
25.
Zurück zum Zitat Moretti R, Torre P, Antonello RM, Cazzato G, Bava A (2003) Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am J Alzheimers Dis Other Demen 18:265–272PubMedCrossRef Moretti R, Torre P, Antonello RM, Cazzato G, Bava A (2003) Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am J Alzheimers Dis Other Demen 18:265–272PubMedCrossRef
26.
Zurück zum Zitat Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A (2003) Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer’s disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen 18:205–214PubMedCrossRef Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A (2003) Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer’s disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen 18:205–214PubMedCrossRef
27.
Zurück zum Zitat Mortimer JA, Snowdon DA, Markesbery WR (2003) Head circumference, education and risk of dementia: findings from the Nun Study. J Clin Exp Neuropsychol 25:671–679PubMedCrossRef Mortimer JA, Snowdon DA, Markesbery WR (2003) Head circumference, education and risk of dementia: findings from the Nun Study. J Clin Exp Neuropsychol 25:671–679PubMedCrossRef
28.
Zurück zum Zitat Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51:1546–1554PubMed Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51:1546–1554PubMed
29.
Zurück zum Zitat Ngandu T, von Strauss E, Helkala EL, Winblad B, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M (2007) Education and dementia: what lies behind the association? Neurology 69:1442–1450PubMedCrossRef Ngandu T, von Strauss E, Helkala EL, Winblad B, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M (2007) Education and dementia: what lies behind the association? Neurology 69:1442–1450PubMedCrossRef
30.
Zurück zum Zitat Perneczky R, Diehl-Schmid J, Drzezga A, Kurz A (2007) Brain reserve capacity in frontotemporal dementia: a voxel-based 18F-FDG PET study. Eur J Nucl Med Mol Imaging 34:1082–1087PubMedCrossRef Perneczky R, Diehl-Schmid J, Drzezga A, Kurz A (2007) Brain reserve capacity in frontotemporal dementia: a voxel-based 18F-FDG PET study. Eur J Nucl Med Mol Imaging 34:1082–1087PubMedCrossRef
31.
Zurück zum Zitat Perneczky R, Diehl-Schmid J, Pohl C, Drzezga A, Kurz A (2007) Non-fluent progressive aphasia: cerebral metabolic patterns and brain reserve. Brain Res 1133:178–185PubMedCrossRef Perneczky R, Diehl-Schmid J, Pohl C, Drzezga A, Kurz A (2007) Non-fluent progressive aphasia: cerebral metabolic patterns and brain reserve. Brain Res 1133:178–185PubMedCrossRef
32.
Zurück zum Zitat Perneczky R, Drzezga A, Diehl-Schmid J, Schmid G, Wohlschlager A, Kars S, Grimmer T, Wagenpfeil S, Monsch A, Kurz A (2006) Schooling mediates brain reserve in Alzheimer’s disease: findings of fluoro-deoxy-glucose-positron emission tomography. J Neurol Neurosurg Psychiatry 77:1060–1063PubMedCrossRef Perneczky R, Drzezga A, Diehl-Schmid J, Schmid G, Wohlschlager A, Kars S, Grimmer T, Wagenpfeil S, Monsch A, Kurz A (2006) Schooling mediates brain reserve in Alzheimer’s disease: findings of fluoro-deoxy-glucose-positron emission tomography. J Neurol Neurosurg Psychiatry 77:1060–1063PubMedCrossRef
33.
Zurück zum Zitat Perneczky R, Hartmann J, Grimmer T, Drzezga A, Kurz A (2007) Cerebral metabolic correlates of the clinical dementia rating scale in mild cognitive impairment. J Geriatr Psychiatry Neurol 20:84–88PubMedCrossRef Perneczky R, Hartmann J, Grimmer T, Drzezga A, Kurz A (2007) Cerebral metabolic correlates of the clinical dementia rating scale in mild cognitive impairment. J Geriatr Psychiatry Neurol 20:84–88PubMedCrossRef
34.
Zurück zum Zitat Perneczky R, Wagenpfeil S, Komossa K, Grimmer T, Diehl J, Kurz A (2006) Mapping scores onto stages: mini-mental state examination and clinical dementia rating. Am J Geriatr Psychiatry 14:139–144PubMedCrossRef Perneczky R, Wagenpfeil S, Komossa K, Grimmer T, Diehl J, Kurz A (2006) Mapping scores onto stages: mini-mental state examination and clinical dementia rating. Am J Geriatr Psychiatry 14:139–144PubMedCrossRef
35.
Zurück zum Zitat Ratnavalli E, Brayne C, Dawson K, Hodges JR (2002) The prevalence of frontotemporal dementia. Neurology 58:1615–1621PubMed Ratnavalli E, Brayne C, Dawson K, Hodges JR (2002) The prevalence of frontotemporal dementia. Neurology 58:1615–1621PubMed
36.
Zurück zum Zitat Reitan R (1985) Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 8:271–276CrossRef Reitan R (1985) Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 8:271–276CrossRef
37.
Zurück zum Zitat Rosen HJ, Narvaez JM, Hallam B, Kramer JH, Wyss-Coray C, Gearhart R, Johnson JK, Miller BL (2004) Neuropsychological and functional measures of severity in Alzheimer disease, frontotemporal dementia, and semantic dementia. Alzheimer Dis Assoc Disord 18:202–207PubMed Rosen HJ, Narvaez JM, Hallam B, Kramer JH, Wyss-Coray C, Gearhart R, Johnson JK, Miller BL (2004) Neuropsychological and functional measures of severity in Alzheimer disease, frontotemporal dementia, and semantic dementia. Alzheimer Dis Assoc Disord 18:202–207PubMed
38.
Zurück zum Zitat Stern Y (2002) What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 8:448–460PubMedCrossRef Stern Y (2002) What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 8:448–460PubMedCrossRef
39.
Zurück zum Zitat Stern Y, Albert S, Tang MX, Tsai WY (1999) Rate of memory decline in AD is related to education and occupation: cognitive reserve? Neurology 53:1942–1947PubMed Stern Y, Albert S, Tang MX, Tsai WY (1999) Rate of memory decline in AD is related to education and occupation: cognitive reserve? Neurology 53:1942–1947PubMed
40.
Zurück zum Zitat Swanberg MM (2007) Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord 21:164–166PubMedCrossRef Swanberg MM (2007) Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord 21:164–166PubMedCrossRef
41.
Zurück zum Zitat Teri L, McCurry SM, Edland SD, Kukull WA, Larson EB (1995) Cognitive decline in Alzheimer’s disease: a longitudinal investigation of risk factors for accelerated decline. J Gerontol A Biol Sci Med Sci 50A:M49–M55PubMed Teri L, McCurry SM, Edland SD, Kukull WA, Larson EB (1995) Cognitive decline in Alzheimer’s disease: a longitudinal investigation of risk factors for accelerated decline. J Gerontol A Biol Sci Med Sci 50A:M49–M55PubMed
42.
Zurück zum Zitat Thalmann B, Monsch A (1997) CERAD. The Consortium to Establish a Registry for Alzheimer’s Disease. Neuropsychologische Testbatterie. Memory Clinic Basel, Basel Thalmann B, Monsch A (1997) CERAD. The Consortium to Establish a Registry for Alzheimer’s Disease. Neuropsychologische Testbatterie. Memory Clinic Basel, Basel
43.
Zurück zum Zitat Valenzuela MJ, Sachdev P (2006) Brain reserve and cognitive decline: a non-parametric systematic review. Psychol Med 36:1–9CrossRef Valenzuela MJ, Sachdev P (2006) Brain reserve and cognitive decline: a non-parametric systematic review. Psychol Med 36:1–9CrossRef
Metadaten
Titel
Accelerated clinical decline in well-educated patients with frontotemporal lobar degenerations
verfasst von
Robert Perneczky
Corina Pohl
Susanne Bornschein
Hans Förstl
Alexander Kurz
Janine Diehl-Schmid
Publikationsdatum
01.09.2009
Verlag
D. Steinkopff-Verlag
Erschienen in
European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 6/2009
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-009-0004-6

Weitere Artikel der Ausgabe 6/2009

European Archives of Psychiatry and Clinical Neuroscience 6/2009 Zur Ausgabe

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.